0001140361-23-054516.txt : 20231122
0001140361-23-054516.hdr.sgml : 20231122
20231122193430
ACCESSION NUMBER: 0001140361-23-054516
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231120
FILED AS OF DATE: 20231122
DATE AS OF CHANGE: 20231122
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Chen Ruoyu
CENTRAL INDEX KEY: 0001982080
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-51173
FILM NUMBER: 231434796
MAIL ADDRESS:
STREET 1: 12730 HIGH BLUFF DRIVE
STREET 2: SUITE 250
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: GYRE THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001124105
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 562020050
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12770 HIGH BLUFF DRIVE, SUITE 150
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (619) 949-3681
MAIL ADDRESS:
STREET 1: 12770 HIGH BLUFF DRIVE, SUITE 150
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
FORMER COMPANY:
FORMER CONFORMED NAME: CATALYST BIOSCIENCES, INC.
DATE OF NAME CHANGE: 20150820
FORMER COMPANY:
FORMER CONFORMED NAME: TARGACEPT INC
DATE OF NAME CHANGE: 20000919
4
1
form4.xml
X0508
4
2023-11-20
0001124105
GYRE THERAPEUTICS, INC.
GYRE
0001982080
Chen Ruoyu
C/O GYRE THERAPEUTICS, INC.
12770 HIGH BLUFF DRIVE, SUITE 150
SAN DIEGO
CA
92130
true
Chief Financial Officer
false
Stock Option (Right to Buy)
0.75
2023-11-20
4
A
0
578540
0
A
2030-10-31
Common Stock
578540
578540
D
Beijing Continent Pharmaceuticals Co., Ltd, a company organized under the laws of the People's Republic of China ("Beijing Continent"), terminated its 2021 Stock Incentive Plan (the "2021 Plan") and each option (a "BC Option") to purchase common shares of Beijing Continent outstanding under the 2021 Plan was terminated and replaced with options granted pursuant to a sub-plan for Chinese participants under the Issuer's 2023 Omnibus Incentive Plan that are substantially similar in all material respects to the BC Options previously outstanding under the 2021 Plan.
These options are vested in full.
/s/ Ruoyu Chen
2023-11-22